NCT05422963Unknown不适用
Multiple-Center Retrospective Study of Severe and Critical COVID-19 in Shanghai
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 1,000
- 试验地点
- 1
- 主要终点
- 28-day mortality
研究概览
简要总结
This study is to clarify the clinical characteristics of severe and critical COVID-19 from March 1st ,2022 to June 9th, 2022 in Shanghai and to explore the relationship between the characteristics and prognosis in these patients.
详细描述
- To Describe the clinical characteristics of severe and critical COVID-19.
- To analyze the relationship between the clinical characteristics and their clinical prognosis;
- To analyze the relationship between clinical intervention and their clinical prognosis.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •severe and critical covid-19 patients who met the "Diagnosis and Treatment Plan for new Coronavirus Pneumonia (Ninth Edition)"
- •admission time more than 24 hours
排除标准
- •admission time less than 24 hours
结局指标
主要结局
28-day mortality
时间窗: one year
28-day mortality of severe and critical COVID-19
次要结局
- 60-day mortality(one year)
- the percentage of organ failure(one year)
- ICU length of stay(one year)
- time for virus to turn negative(one year)
- The overall description(one year)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.Indolent B-Cell Non-Hodgkin LymphomaCOVID-19Chronic Lymphocytic LeukemiaNCT05803395Gruppo Italiano Malattie EMatologiche dell'Adulto954
已完成
不适用
COVID-19 and Disease Progression to the Severe Form: a Study on the Use of Monoclonal Antibodies Against SARS-CoV-2COVID-19NCT05268601University of Milano Bicocca251
Enrolling By Invitation
不适用
Risk Identification of Long-term ComplicationsSevere COVID-19NCT06235866Wuhan Central Hospital500
已完成
不适用
Analysis of Laboratory Markers for Severe COVID-19Coronavirus Infection COVID-19NCT06460753Karaganda Medical University193
已完成
不适用
Predictors of Severe COVID-19 OutcomesCOVID-19Acute Respiratory Distress SyndromeNCT04388813Verily Life Sciences LLC494